References
1. Davies L, Ouellette M, Hunter M, Welch HG. The increasing incidence
of small thyroid cancers: where are the cases coming from? Laryngoscope.
2010 Dec;120(12):2446–2451.
2. Ito Y, Miyauchi A, Oda H. Low-risk papillary microcarcinoma of the
thyroid: A review of active surveillance trials. Eur J Surg Oncol.
2018;44(3):307–315.
3. Ito Y, Miyauchi A, Inoue H, Fukushima M, Kihara M, Higashiyama T, et
al. An observational trial for papillary thyroid microcarcinoma in
Japanese patients. World J Surg. 2010 Jan;34(1):28–35.
4. Sugitani I, Ito Y, Miyauchi A, Imai T, Suzuki S. Active Surveillance
Versus Immediate Surgery: Questionnaire Survey on the Current Treatment
Strategy for Adult Patients with Low-Risk Papillary Thyroid
Microcarcinoma in Japan. Thyroid. 2019 Sep 25;29(11):1563–1571.
5. Sakai T, Sugitani I, Ebina A, Fukuoka O, Toda K, Mitani H, et al.
Active surveillance for t1bn0m0 papillary thyroid carcinoma. Thyroid.
2019 Jan 8;29(1):59–63.
6. Pacini F. Observation for newly diagnosed micro-papillary thyroid
cancer: is now the time? J Endocrinol Invest. 2015 Jan;38(1):101–102.
7. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov
YE, et al. 2015 American Thyroid Association Management Guidelines for
Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer:
The American Thyroid Association Guidelines Task Force on Thyroid
Nodules and Differentiated Thyroid Cancer. Thyroid. 2016
Jan;26(1):1–133.
8. Lee WK, Lee J, Kim H, Lee SG, Choi SH, Jeong S, et al. Peripheral
location and infiltrative margin predict invasive features of papillary
thyroid microcarcinoma. Eur J Endocrinol. 2019 Aug;181(2):139–149.
9. Chen Y, Sadow PM, Suh H, Lee KE, Choi JY, Suh YJ, et al. BRAF(V600E)
Is Correlated with Recurrence of Papillary Thyroid Microcarcinoma: A
Systematic Review, Multi-Institutional Primary Data Analysis, and
Meta-Analysis. Thyroid. 2016 Feb;26(2):248–255.
10. Kim KJ, Kim SG, Tan J, Shen X, Viola D, Elisei R, et al. BRAF V600E
status may facilitate decision-making on active surveillance of low-risk
papillary thyroid microcarcinoma. Eur J Cancer. 2020;124:161–169.
11. Lin K-L, Wang O-C, Zhang X-H, Dai X-X, Hu X-Q, Qu J-M. The BRAF
mutation is predictive of aggressive clinicopathological characteristics
in papillary thyroid microcarcinoma. Ann Surg Oncol. 2010
Dec;17(12):3294–3300.
12. Niemeier LA, Kuffner Akatsu H, Song C, Carty SE, Hodak SP, Yip L, et
al. A combined molecular-pathologic score improves risk stratification
of thyroid papillary microcarcinoma. Cancer. 2012 Apr
15;118(8):2069–2077.
13. Zheng X, Wei S, Han Y, Li Y, Yu Y, Yun X, et al. Papillary
microcarcinoma of the thyroid: clinical characteristics and BRAF(V600E)
mutational status of 977 cases. Ann Surg Oncol. 2013
Jul;20(7):2266–2273.
14. Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP,
Talamonti MS, et al. Extent of surgery affects survival for papillary
thyroid cancer. Ann Surg. 2007 Sep;246(3):375–81; discussion 381.
15. Centers for Disease Control and Prevention. National Vital
Statistics Reports, Volume 69 (12) [Internet]. [cited 2020 Nov
1]. Available from: https://www.cdc.gov/nchs/products/index.htm
16. Ito Y, Miyauchi A, Kihara M, Higashiyama T, Kobayashi K, Miya A.
Patient age is significantly related to the progression of papillary
microcarcinoma of the thyroid under observation. Thyroid. 2014
Jan;24(1):27–34.
17. Lang BH-H, Wong CKH. A cost-effectiveness comparison between early
surgery and non-surgical approach for incidental papillary thyroid
microcarcinoma. Eur J Endocrinol. 2015 Sep;173(3):367–375.
18. Sugitani I, Ito Y, Takeuchi D, Nakayama H, Masaki C, Shindo H, et
al. Indications and Strategy for Active Surveillance of Adult Low-Risk
Papillary Thyroid Microcarcinoma: Consensus Statements from the Japan
Association of Endocrine Surgery Task Force on Management for Papillary
Thyroid Microcarcinoma. Thyroid. 2020 Nov 2;
19. Brito JP, Ito Y, Miyauchi A, Tuttle RM. A clinical framework to
facilitate risk stratification when considering an active surveillance
alternative to immediate biopsy and surgery in papillary microcarcinoma.
Thyroid. 2016 Jan;26(1):144–149.
20. Kimura E, Nikiforova M, Zhu Z, Knauf J, Nikiforov Y, Fagin J. High
Prevalence of BRAF Mutations in Thyroid Cancer: Genetic Evidence for
Constitutive Activation of the RET/PTC-RAS-BRAF Signaling Pathway in
Papillary Thyroid Carcinoma1.
21. Sturgis EM, Sherman SI. Should papillary thyroid carcinoma be
observed?: a word of caution. Arch Otolaryngol Head Neck Surg. 2010
May;136(5):444–446.
22. Pitt SC, Saucke MC, Roman BR, Alexander SC, Voils CI. The Influence
of Emotions on Treatment Decisions About Low-Risk Thyroid Cancer: A
Qualitative Study. Thyroid. 2021 Nov 26;
23. Haymart MR, Miller DC, Hawley ST. Active Surveillance for Low-Risk
Cancers - A Viable Solution to Overtreatment? N Engl J Med. 2017 Jul
20;377(3):203–206.
24. Venkatesh S, Pasternak JD, Beninato T, Drake FT, Kluijfhout WP, Liu
C, et al. Cost-effectiveness of active surveillance versus
hemithyroidectomy for micropapillary thyroid cancer. Surgery.
2017;161(1):116–126.